Articles tagged with Colorectal Cancer
TTUHSC researchers received funding for pilot studies on photothermal tumor therapy, clear cell renal cell carcinoma, and colorectal cancer screening in underserved areas. The grants support the purchase of a cell sorter and address regional health disparities.
Researchers discovered that inhibiting the BRAF/EGFR/MEK pathway significantly reduced cancer stemness and drug resistance in primary colorectal cancer cells. The study also identified a triple combination treatment against BRAF, EGFR, and MEK as a promising approach to block these activities and develop effective treatments.
A multilevel primary care intervention, including electronic health record reminders and patient outreach, improved timely follow-up of overdue abnormal cancer screening test results for breast, cervical, colorectal, and lung cancer. The intervention was found to be effective in reducing missed screenings.
A VHIO-led study has identified DPPA3 as a regulator of dormant cancer cells and chemoresistance in colorectal cancer. High levels of DPPA3 are found to predict disease relapse, while HIF1 is proposed as a potential therapeutic target to sensitize CRC cells to chemotherapy.
A recent study from China found that comprehensive treatment, including CRS, chemotherapy, and HIPEC, significantly improved patient outcomes for CRC with SPM. Complete cytoreductive surgery was an independent predictor of improved survival. More research is needed to refine treatment strategies.
A new Canadian guideline aims to promote health equity among marginalized groups by providing 16 preventive care recommendations. The guidelines focus on removing barriers to healthcare, prioritizing people from disadvantaged groups, and improving access to essential screenings and interventions.
Researchers explore kinase inhibitors as targeted therapies for specific CRC subsets, offering hope for improved treatment options. Key findings suggest that uncovering essential kinases for tumor growth can lead to more effective treatment strategies in metastatic or later-stage CRC patients.
Researchers have identified new genetic markers to detect Lynch syndrome-associated colorectal cancer with 92% accuracy. The discovery could lead to a non-invasive screening option using stool samples, reducing the need for annual colonoscopies and invasive tests.
Researchers found higher 5-year survival rates among Kaiser Permanente patients compared to National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) estimates. Improved screening rates, cancer treatment pathways, and coordinated care may have contributed to these higher survival rates.
Researchers have discovered two FDA-approved and EMA-approved drugs that inhibit prmt5, a protein linked to promoting tumor growth in several cancers. These repurposed drugs show promise in reducing cancer cell proliferation and tumor growth.
A large study found that people with an evening chronotype were more likely to engage in unhealthy lifestyle behaviors such as smoking, poor sleep, and physical inactivity. These individuals had a 72% higher risk of developing diabetes compared to those with a morning chronotype.
A new study published in Clinical Gastroenterology and Hepatology found an association between breastfeeding as an infant and an increased risk of colorectal cancer in adulthood. Researchers analyzed data from over 158,000 women and discovered that breastfed individuals were 23% more likely to develop colorectal cancer later in life.
Research published in BMJ Oncology reveals a global increase of 79% in new cancer cases among those under 50 between 1990 and 2019. Breast cancer accounted for the highest number of early onset cases, while cancers of the windpipe and prostate rose the fastest.
Researchers at Karolinska Institutet found that statin treatment was associated with a lower risk of developing and dying from colorectal cancer in patients with ulcerative colitis. After a follow-up period of 5.6 years, the study showed that 70 statin users had been diagnosed with colorectal cancer compared to 90 non-statin users.
A novel liquid biopsy technology developed by UCSC Assistant Professor Daniel Kim's lab leverages RNA 'dark matter' to enhance cancer diagnosis. The test detects both protein-coding and repetitive noncoding RNAs in the blood, showing improved sensitivity for early-stage cancer detection.
Mayo Clinic researchers found that cells expressing PD-1 and PD-L1 within a certain distance of each other can predict the success of immunotherapy in patients with colorectal cancer. This spatial analysis may help select patients most likely to benefit from treatment, improving outcomes and minimizing unnecessary treatments.
Researchers from Helmholtz Munich and TU Dresden develop AI-powered biomarker detection that outperforms previous approaches. The algorithm achieves high sensitivity on resection tissue samples and shows promise as a pre-screening tool for biopsy tissue.
A systematic review and meta-analysis of 18 clinical trials involving 2.1 million individuals found no significant lifetime gain from common cancer screening tests. However, colorectal cancer screening with sigmoidoscopy may have a potential benefit, according to the study.
Researchers at the Salk Institute discovered that high-fat diets change gut bacteria and bile acids, leading to inflammation and affecting intestinal stem cell replenishment. The altered bile acids cause inflammation and increase cancer risk in mice.
A new commentary suggests that vitamin D supplementation can improve survival outcomes for patients with digestive tract cancers, particularly those with a high-risk genetic makeup. The study found that patients with antibodies to control the production of mutated p53 protein saw improved survival rates when taking daily vitamin D3 sup...
A statistician at Virginia Commonwealth University has been awarded a $1.7 million grant to investigate the long-term effects of neighborhood exposures and racial segregation on cancer risk. The researcher aims to better understand how geographic and socioeconomic factors contribute to disparities in cancer incidence and mortality.
A new study estimates that cancer screenings have saved the US at least $6.5 trillion and led to 12 million more years of life, with significant economic impact from breast, colon, cervical, and lung cancer screenings.
Researchers identified 2476 nonsynonymous mutations in SA-CRC, including four newly discovered driver genes. The study also found distinct genomic profiles of SA-CRC compared to other colorectal cancers.
A Harvard T.H. Chan School of Public Health study found that chronic exposure to fine particulate air pollutants (PM2.5) and nitrogen dioxide (NO2) increases the risk of colorectal and prostate cancers in older adults. NO2 exposure was also associated with an increased risk of breast cancer, while PM2.5 exposure had mixed results.
A meta-analysis of multiple studies found no association between depression and anxiety and most types of cancer. However, the study found a link between depression and anxiety with a 6% higher risk of developing lung cancer and smoking-related cancers.
A study by Harvard T.H. Chan School of Public Health found that chronic exposure to fine particulate air pollutants (PM2.5) and nitrogen dioxide (NO2) may increase non-lung cancer risk in older adults, with significant associations with colorectal and prostate cancers.
A new study found that 81% of women report persistent GI symptoms years after diagnosis, with abdominal bloating and gas being the most common. The analysis also showed that severe GI symptoms are linked to poor quality of life, social activities, and body image satisfaction.
The American College of Physicians recommends starting colorectal cancer screening at age 50 for asymptomatic adults with average risk. The guideline aims to balance benefits and harms of screening in this population. Screening in younger adults may not offer significant net benefit due to lower incidence rates.
Researchers found that expression of transcription factors contributes to different subtypes of colorectal cancers. The degree of DNA methylation varies across tissue types, with some cancers having high and others low frequency of methylation gains. Studying transcription factor expression may help determine overall survival in patien...
Researchers identified methylation in normal tissues in some patients with mismatch repair deficiency, leading to undiagnosed Lynch syndrome. This study suggests revising current screening guidelines to include this poorly recognized cause of hereditary cancer.
Researchers discovered that Nerofe and Doxorubicin can downregulate KRAS signaling, leading to enhanced apoptosis in colorectal cancer cells. The combination also activates the immune system against tumor cells, increasing immunostimulatory cytokines and recruiting NK cells and M1 macrophages.
A study found disparities in Hispanic cancer mortality rates, with higher rates for men in certain age groups and women for liver, pancreatic, and uterine cancers. The researchers highlight the need for targeted education and screening efforts to address these disparities.
Researchers developed a biodegradable nanoparticle that reaches dendritic cells in mice with melanoma and colon cancer, activating an immune response. The nanoparticle improves survival rates for these cancers, with half of mice surviving long-term after treatment.
A study by Regenstrief Institute has identified seven risk factors for early onset colorectal cancer in males, providing a framework for clinicians to consider screening recommendations for younger men. The model may help estimate relative risk and identify individuals at higher risk for colorectal cancer.
Researchers have developed a new technique to generically treat several kinds of cancer, showing tumors grew almost three times less and survival rates reached 100% after just one injection. The method targets cancer cells with alpha radiation, sparing healthy tissue.
A newly discovered radionuclide-based agent (CB-2PA-NT) has shown high tumor uptake, sustained retention, and contrast in preclinical models. Targeting neurotensin receptors, CB-2PA-NT expands precision medicine for cancer diagnosis and treatment.
The FRESCO-2 phase III study demonstrated statistically significant improvements in overall survival and progression-free survival in patients with refractory metastatic colorectal cancer treated with fruquintinib. Fruquintinib showed a favorable safety profile, with patients staying on treatment almost twice as long as those on placebo.
Researchers developed a new tool called Orion that integrates histologic and molecular information to improve cancer diagnosis and treatment. The tool uses a digital imaging platform to analyze tumor samples, identifying biomarkers that predict patient outcomes.
A preclinical study has uncovered the role of Y chromosome gene KDM5D in regulating anti-tumor immune responses and promoting metastasis in male patients with KRAS-mutated colorectal cancer. The study reveals that mutant KRAS drives upregulation of KDM5D, leading to reduced cell adhesion and immune recognition by the immune system.
The FRESCO-2 trial shows that fruquintinib significantly improved overall survival and progression-free survival in patients with refractory metastatic colorectal cancer. The median OS was 7.4 months with fruquintinib versus 4.8 months in the placebo arm.
A study by Martin-Luther-University Halle-Wittenberg found a link between high levels of IGF2BP2 and faster-growing bowel cancer tumours with chemotherapy resistance. The protein's role in cell growth and metabolism may lead to the development of new diagnostic procedures and therapeutic strategies.
A keto diet may help reduce body weight and slow tumor growth in cancer patients. However, research found that this diet can cause early-onset cachexia, a lethal wasting disease, in mice with pancreatic and colorectal cancer. Pairing keto with corticosteroids prevented cachexia in mice, allowing them to live longer.
A new study found significant reductions in breast, colorectal and prostate cancers as well as melanoma diagnoses in Alberta during the COVID-19 pandemic. Diagnoses dropped by 43% for melanoma, 36% for colorectal and prostate, and 33% for breast cancer during the 'state of emergency' phase.
A new study found that obesity is associated with an increased risk of certain cancers, with stronger links in female patients for gallbladder and endometrial cancer. The study also revealed differential effects between sexes on colorectal, esophageal, and liver cancer.
Researchers have developed a polygenic risk score for colorectal cancer, which can estimate an individual's likely disease risk and identify those who may benefit from earlier screening. The score can also help determine more appropriate ages to start screening based on genetic risk.
Research from Johns Hopkins Medicine found that Black and Hispanic female breast cancer survivors have higher death rates from second cancers compared to other ethnic groups. The risk of death from a second cancer is 12% higher among non-Hispanic Black survivors and 8% higher among Hispanic survivors.
Researchers found that only 6.8% of cancer patients underwent genetic testing within two years of diagnosis, with lower rates among Black, Hispanic, and Asian patients. The low rates are attributed to lack of integration of test results into cancer management and prevention.
Researchers found specific bacterial species significantly associated with the development of tubular adenomas and sessile serrated adenomas. The study suggests a potential opportunity to intervene through diet or probiotics to prevent colorectal cancer.
The study found that people younger than age 50 with colorectal cancer had lower levels of citrate and differed in protein and carbohydrate metabolism compared to older patients. Red meat consumption and sugar intake are potential risk factors for young-onset colorectal cancer. Higher levels of 4-hydroxyhippuric acid correlated with im...
Researchers found varying microbiome compositions in early-onset (age 45 or younger) and late-onset (age 65 or older) colorectal cancer tumors, with distinct species present in each group. The discovery may help explain the rise in young-onset disease cases without known risk factors.
A new study published in the Journal of the American College of Surgeons predicts a significant increase in cancer cases due to COVID-19 screening delays, with lung, breast, and colorectal cancers most affected. The study found that missed diagnoses during the pandemic may lead to delays in treatment and upstaging of disease.
Researchers have developed new methods to analyze dry-coated drug particles using 3D Raman mapping, which can effectively slow down dissolution rates. Another study introduces a novel technique for detecting complex traditional Chinese medicines, preventing adulteration and counterfeiting.
Researchers have discovered that HER3 plays a crucial role in promoting cell survival in metastatic colorectal and pancreatic cancer. The surrounding liver microenvironment activates HER3, making it an emerging therapeutic target for these types of cancer.
Researchers have created a new measure called the LRRC–QoL to assess health-related quality of life in patients with locally recurrent rectal cancer. The tool captures a wide range of issues affecting these patients, providing a more comprehensive understanding of their experiences.
A new study by researchers from the University of Edinburgh found that double testing with a faecal immunochemical test (FIT) increases the detection rate of bowel cancer to nearly 100%. This approach ensures more cases are identified and can potentially reduce demand for colonoscopies.
Researchers found that fatty liver cells secrete proteins and genetic material that promote the spread of colorectal cancer to the liver. This condition is likely underdiagnosed, affecting over 40% of patients with colorectal cancer, according to a new study published in Cell Metabolism.
Overweight and obesity in early adulthood are associated with increased risks of colorectal cancer and non-colorectal gastrointestinal cancers. The study highlights the need for further exploration into the mechanisms driving these associations.
Researchers at Baylor College of Medicine found that silencing gene p16 can drive colorectal cancer progression in animal models. A combined treatment strategy involving two drugs improved survival rates in tumor-bearing mice, offering new possibilities for targeted therapies.
A new study finds that one-time genomic screening of adults aged 20-60 for hereditary breast and ovarian cancer syndrome, Lynch syndrome, and familial hypercholesterolemia is cost-effective based on quality-adjusted life-year measures. The study suggests that this approach could improve disease management and reduce healthcare costs.
Researchers created organoids from patient tissues to test chemotherapy drugs and identified genetic signatures that predict treatment response, offering high accuracy in personalized drug screening. This breakthrough may help select effective drugs for individual patients, reducing trial and error.